دورية أكاديمية
Divergent pathogenetic outcomes in BALB/c mice following Omicron subvariant infection.
| العنوان: | Divergent pathogenetic outcomes in BALB/c mice following Omicron subvariant infection. |
|---|---|
| المؤلفون: | Powers JM; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599, USA. Electronic address: jpowers@unc.edu., Leist SR; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599, USA., Mallory ML; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599, USA., Yount BL; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599, USA., Gully KL; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599, USA., Zweigart MR; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599, USA., Bailey AB; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599, USA., Sheahan TP; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599, USA; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Harkema JR; Department of Pathobiology & Diagnostic Investigation, Michigan State University, East Lansing, MI, USA., Baric RS; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599, USA; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. |
| المصدر: | Virus research [Virus Res] 2024 Mar; Vol. 341, pp. 199319. Date of Electronic Publication: 2024 Jan 19. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8410979 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7492 (Electronic) Linking ISSN: 01681702 NLM ISO Abbreviation: Virus Res Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Amsterdam : Elsevier Science, c1984- |
| مواضيع طبية MeSH: | SARS-CoV-2* , Weight Loss*, Animals ; Mice ; Mice, Inbred BALB C ; Mutation ; Phenotype |
| مستخلص: | Following the emergence of B.1.1.529 Omicron, the SARS-CoV-2 virus evolved into a significant number of sublineage variants that possessed numerous mutations throughout the genome, but particularly within the spike glycoprotein (S) gene. For example, the BQ.1.1 and the XBB.1 and XBB.1.5 subvariants contained 34 and 41 mutations in S, respectively. However, these variants elicited largely replication only or mild disease phenotypes in mice. To better model pathogenic outcomes and measure countermeasure performance, we developed mouse adapted versions (BQ.1.1 MA; XBB.1 MA; XBB.1.5 MA) that reflect more pathogenic acute phase pulmonary disease symptoms of SARS-CoV-2, as well as derivative strains expressing nano-luciferase (nLuc) in place of ORF7 (BQ.1.1 nLuc; XBB.1 nLuc; XBB.1.5 nLuc). Amongst the mouse adapted (MA) viruses, a wide range of disease outcomes were observed including mortality, weight loss, lung dysfunction, and tissue viral loads in the lung and nasal turbinates. Intriguingly, XBB.1 MA and XBB.1.5 MA strains, which contained identical mutations throughout except at position F486S/P in S, exhibited divergent disease outcomes in mice (Ao et al., 2023). XBB.1.5 MA infection was associated with significant weight loss and ∼45 % mortality across two independent studies, while XBB.1 MA infected animals suffered from mild weight loss and only 10 % mortality across the same two independent studies. Additionally, the development and use of nanoluciferase expressing strains provided moderate throughput for live virus neutralization assays. The availability of small animal models for the assessment of Omicron VOC disease potential will enable refined capacity to evaluate the efficacy of on market and pre-clinical therapeutics and interventions. Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: R.S.B and S.R.L hold a patent for the SARS-CoV-2 MA10 virus, patent number (US 11,225,508 B1, “Mouse-adapted SARS-CoV-2 Viruses And Methods Of Use Thereof”). (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.) |
| معلومات مُعتمدة: | P01 AI158571 United States AI NIAID NIH HHS; P01 AI167966 United States AI NIAID NIH HHS; P30 CA016086 United States CA NCI NIH HHS; R01 AI110700 United States AI NIAID NIH HHS |
| فهرسة مساهمة: | Keywords: BQ.1.1; Mouse models; Pathogenesis; SARS-CoV-2; XBB.1; XBB.1.5 |
| تواريخ الأحداث: | Date Created: 20240115 Date Completed: 20240214 Latest Revision: 20240520 |
| رمز التحديث: | 20240520 |
| مُعرف محوري في PubMed: | PMC10835285 |
| DOI: | 10.1016/j.virusres.2024.199319 |
| PMID: | 38224840 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1872-7492 |
|---|---|
| DOI: | 10.1016/j.virusres.2024.199319 |